About: Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Sector: Healthcare
Industry: Biotechnology
Latest price: $4.98 (+6.87%)
CING NASDAQ Cingulate Inc
Cingulate Inc share price
Atividade de preço de CING
Último preço
$ 4,980
Variação (24h)
0,32 USD (6,87%)
Volume
79.12K
Volume (média 4 sem.)
-
Abertura
$ 4,64
Variação do dia
$ 4,61 - $ 4,98
Fechamento anterior
$ 4,66
Último negócio
23 Oct, 8:00 pm GMT+0
Atrasado
23 Oct, 8:00 pm GMT+0
CING price performance
Atrasado
23 Oct, 8:00 pm GMT+0
quote.marketSignals